AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) major shareholder Equity Opportunities Fu Growth bought 4,347,827 shares of the company’s stock in a transaction dated Monday, April 8th. The shares were acquired at an average cost of $1.14 per share, for a total transaction of $4,956,522.78. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.
NASDAQ:AVEO traded down $0.02 during mid-day trading on Monday, reaching $1.00. The stock had a trading volume of 2,940,007 shares, compared to its average volume of 7,235,716. AVEO Pharmaceuticals, Inc. has a 1-year low of $0.49 and a 1-year high of $3.59. The company has a market capitalization of $141.78 million, a price-to-earnings ratio of -5.26 and a beta of 1.19.
AVEO Pharmaceuticals (NASDAQ:AVEO) last issued its earnings results on Thursday, March 14th. The biopharmaceutical company reported ($0.03) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.06) by $0.03. The company had revenue of $1.48 million during the quarter, compared to analyst estimates of $2.48 million. As a group, analysts expect that AVEO Pharmaceuticals, Inc. will post -0.16 earnings per share for the current fiscal year.
A number of brokerages have recently issued reports on AVEO. Zacks Investment Research raised AVEO Pharmaceuticals from a “hold” rating to a “buy” rating and set a $0.75 target price on the stock in a research report on Tuesday, March 19th. HC Wainwright reiterated a “hold” rating and issued a $1.00 price target on shares of AVEO Pharmaceuticals in a research note on Monday, March 18th. FBR & Co set a $3.00 price target on AVEO Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, December 20th. BidaskClub upgraded AVEO Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, January 15th. Finally, Robert W. Baird began coverage on AVEO Pharmaceuticals in a research note on Thursday, January 3rd. They issued an “outperform” rating and a $3.00 price target for the company. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and four have given a buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of $1.96.
ILLEGAL ACTIVITY NOTICE: “Insider Buying: AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) Major Shareholder Acquires 4,347,827 Shares of Stock” was published by Baseball Daily News and is the sole property of of Baseball Daily News. If you are accessing this piece of content on another domain, it was illegally stolen and reposted in violation of U.S. and international copyright laws. The original version of this piece of content can be viewed at https://www.baseballdailydigest.com/news/2019/04/15/aveo-pharmaceuticals-inc-aveo-major-shareholder-equity-opportunities-fu-growth-purchases-4347827-shares-of-stock.html.
About AVEO Pharmaceuticals
AVEO Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes a portfolio of targeted medicines for oncology and other areas of unmet medical need. It markets its lead candidate, tivozanib, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC).
Receive News & Ratings for AVEO Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.